Clinical trials: 5-FU, completed
Advanced Gastric Cancer
A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China
This is a multi-center, prospective and observational clinical study. Eligible patients will accept generalized chemotherapy according to the investigator's assessment.
- Trial name
- NCT01472250
- Testing
- Clinical chemo-drugs
- Where
- China
- Volunteers
- 498 people
- Sponsor
- Peking University
Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
The purpose of the study is to determine the most tolerable and safe dose of ZD6474 (Zactima, Vandetanib) when given with standard chemotherapy, radiation therapy and surgery in patients with cancer of the esophagus
- Conditions
- Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Cancer of the Stomach
- Trial name
- NCT01183559
- Testing
- Vandetanib, 5 Fluorouracil (FU), Carboplatin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Fox Chase Cancer Center
Adenocarcinoma of the Rectum, Stage II Rectal Cancer
Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer
This phase I trial is studying the side effects and best dose of bevacizumab when given together with fluorouracil and external-beam radiation therapy in treating patients with stage II or stage III rectal cancer.
- Conditions
- Adenocarcinoma of the Rectum, Stage II Rectal Cancer, Stage III Rectal Cancer
- Trial name
- NCT00052559
- Testing
- bevacizumab, fluorouracil, external beam radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Neoplasms
FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
This phase I trial studies the side effects and optimal dose of PF-04136309 when given with combination chemotherapy (FOLFIRINOX; 5-fluorouracil, leucovorin, irinotecan, oxaliplatin) in treating patients with locally advanced or…
- Trial name
- NCT01413022
- Testing
- Oxaliplatin, Irinotecan, Leucovorin
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Washington University School of Medicine
Metastatic Colorectal Cancer
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer
Drugs used against cancer work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as CMAB009, can block tumor growth in different ways.
- Trial name
- NCT03206151
- Testing
- CMAB009, Irinotecan, Folinic acid
- Where
- 2 sites in China
- Volunteers
- 520 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Breast Cancer
Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways after surgery may kill more tumor cells.
- Trial name
- NCT00024102
- Testing
- Standard Treatment, capecitabine
- Where
- 334 sites in United States, Canada and 1 more
- Volunteers
- 633 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Cancer
Radiation w/FOLFIRINOX-Losartan for Pancreatic Cancer
This is a Phase II clinical trial, which tests the safety and effectiveness of an investigational combination of drugs to learn whether the combination of drugs works in treating a specific cancer.
- Trial name
- NCT01821729
- Testing
- FOLFIRINOX, Losartan, Proton Beam Radiation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Gastric Adenocarcinoma
Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
This is a study of pembrolizumab (MK-3475) as first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Trial name
- NCT02494583
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Volunteers
- 763 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Cancer
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
This double-blind, placebo-controlled, randomized, multicenter, international, parallel arm study will evaluate the efficacy and safety of pertuzumab in combination with trastuzumab, fluoropyrimidine and cisplatin as first-line…
- Trial name
- JACOB (NCT01774786)
- Testing
- 5-Fluorouracil, Capecitabine, Cisplatin
- Where
- 172 sites in United States, Australia and 30 more
- Volunteers
- 780 people
- Sponsor
- Hoffmann-La Roche
Head and Neck Cancer
Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer
The main purpose of this study is to explore and compare the efficacy of Cetuximab (ERBITUX®) added to two concurrent chemoradiotherapy platforms of different intensity in locally advanced head and neck cancer.
- Trial name
- EPIC (NCT00468169)
- Testing
- Cetuximab, 5-FU, Hydroxyurea
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Chicago
Carcinoma, Hepatocellular
A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
The main purpose of this study is to determine if the advised dose of ramucirumab is safe to be taken with chemotherapy treatment in participants with advanced liver tumors.
- Trial name
- NCT02069041
- Testing
- Ramucirumab, FOLFOX4
- Where
- 3 sites in Taiwan
- Volunteers
- 8 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer, Cytokine-induced Killer Cells
Chemotherapy Combined With CIK Treating Colon Cancer
Cytokine-induced killer cells (CIK) is an auxiliary antitumor treatment. The investigators aim to evaluate the clinical efficacy of chemotherapy combined with CIK in the treatment of postoperative colorectal cancer patients.
- Conditions
- Colorectal Cancer, Cytokine-induced Killer Cells, Postoperative Complications, Survival
- Trial name
- NCT03084809
- Testing
- Cytokine-induced killer cells+ FOLFOX4, FOLFOX4
- Volunteers
- 46 people
- Sponsor
- China Meitan General Hospital
Esophageal Cancer, Gastric Cancer
Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00020787
- Testing
- G17DT Immunogen, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Colorectal Carcinoma
A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)
The primary objective of this study is to investigate the safety and tolerability of the anti-vascular endothelial growth factor receptor-2 (anti-VEGFR-2) monoclonal antibody Ramucirumab (IMC-1121B) in combination with…
- Trial name
- NCT01286818
- Testing
- Ramucirumab (IMC-1121B), Irinotecan, levofolinate
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Eli Lilly and Company
Metastatic Colorectal Cancer
Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients
National trial, multicenter, randomized, phase II assessing FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from circulating DNA analysis.
- Trial name
- PANIRINOX (NCT02980510)
- Testing
- Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan
- Where
- 6 sites in France
- Volunteers
- 219 people
- Sponsor
- UNICANCER
Peritoneal Carcinomatosis, Gastric Cancer
Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer
The aims of this study are to investigate whether multimodal treatment of peritoneal carcinomatosis from gastric cancer is feasible and to evaluate the clinical outcomes and clinical effectiveness of neoadjuvant systemic…
- Trial name
- NCT01379482
- Testing
- Multimodal treatment
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Uppsala University
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma
Gastric or gastroesophageal junction adenocarcinoma is commonly treated with chemotherapy before and after surgery. The chemotherapy regimen used in our institution, called DCF (docetaxel,cisplatic, 5-fluorouracil) is active…
- Trial name
- NCT01932580
- Testing
- FLOT (5-fluorouracil, oxaliplatin, docetaxel)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McGill University
Locally Advanced Rectal Cancer (LARC)
A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer
This is an exploratory, open-label, single arm, non-randomized, multicenter, phase II clinical trial to determine the efficacy and clinical complete response rate in patients with rectal cancer and tumor preoperative evaluation…
- Trial name
- NCT04009876
- Testing
- nal-IRI, Surgical resection, Watch-and-wait
- Where
- 4 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fundación de investigación HM
Kidney Cancer
Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer
RATIONALE: Interferon alfa may interfere with the growth of tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Trial name
- NCT00053820
- Testing
- aldesleukin, recombinant interferon alfa, fluorouracil
- Where
- 12 sites in Belgium, Germany and 2 more
- Volunteers
- 670 people
- Sponsor
- Medical Research Council
Pancreatic Cancer, Cachexia
Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia
This study is being conducted to examine the safety of the investigational drug, Xilonix(™), in addition to standard doses of Onivyde® (nanoliposomal irinotecan) and 5- fluorouracil (5FU)/folinic acid (leucovorin) for pancreatic…
- Conditions
- Pancreatic Cancer, Cachexia, Weight Loss
- Trial name
- OnFX (NCT03207724)
- Testing
- Xilonix plus Onivyde and 5FU
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Andrew Hendifar, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.